The AK0406 FDA Phase 2 trial now has the regulator’s go-ahead to begin. On 13 October 2026, Shanghai-based ArkBio announced that the US Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for AK0406, an experimental long-acting antiviral designed to prevent influenza. The planned study will be multicentre, randomised, double-blind and placebo-controlled, in adults, and will run during an influenza season.
The clearance is a permission to test, not a sign that the drug works. AK0406 is not approved anywhere to prevent influenza, and the company has not released any human efficacy data. This report explains what is planned, what the drug is, how far development has got and what remains unknown.
AK0406 FDA Phase 2 trial: what is planned
- Design: multicentre, randomised, double-blind, placebo-controlled study in adults.
- Primary aim: to evaluate AK0406 for influenza prevention, according to the company.
- Other measures: safety, tolerability, pharmacokinetics (how the body handles the drug) and immunogenicity (whether the immune system reacts to it).
- Population: described as the general population in the United States.
- Not disclosed: number of participants, sites, dose, dosing schedule, start date, treatment duration and exact endpoint definitions.
One third-party summary lists safety and tolerability as the primary measures, which conflicts with the company’s description of influenza prevention as the primary objective. We have gone with the company’s wording, and a registry entry will settle it once the study is listed on ClinicalTrials.gov; we found none yet.
What the AK0406 FDA Phase 2 trial is testing
ArkBio describes AK0406 as a long-acting antiviral drug-Fc conjugate (AFC). Several small-molecule antiviral drugs are attached to the Fc region of an antibody, the tail section that helps antibodies persist in the body. The idea is to combine direct antiviral activity with Fc-mediated immune clearance, so the drug both blocks the virus and helps the body clear it. It is not a vaccine, and it does not rely on the recipient building their own immune response.
The company says laboratory work showed broad-spectrum, potent activity against influenza A and B strains. No figures were given. The antiviral component, its target and the length of protection have not been disclosed in the materials we reviewed.
Where development stands before the AK0406 FDA Phase 2 trial
- February 2026: Australian ethics approval to start a Phase 1 trial in healthy adults.
- July 2026: dosing completed across all cohorts; the study moved into follow-up.
- August 2026: China’s drug regulator cleared an IND for AK0406 for influenza prevention.
- 13 October 2026: FDA cleared the IND for the US Phase 2 trial.
No Phase 1 results on safety or drug levels have been published. A trial listing summarised by a third party shows an enrolment of 32, but we could not confirm which study that refers to. ArkBio says it plans to advance Phase 2 development in the United States and China in parallel.
What FDA clearance means for the AK0406 FDA Phase 2 trial
An IND is the application a sponsor files before testing an unapproved drug in people in the US. As explained in the FDA’s overview of the IND process, a study can generally begin 30 days after the application is received unless the agency objects. Clearing an IND means the agency did not find a reason to stop the trial. It is not a judgment about whether the drug will work, and it differs from approval for sale, which requires evidence from later-stage trials.
Why long-acting flu prevention is being pursued
Vaccination remains the main tool against influenza. ArkBio notes that circulating viruses change and that vaccine protection can be weaker in older adults and people with weakened immune systems. Citing the US Centers for Disease Control and Prevention, the company says the 2025-26 US season caused at least 32 million illnesses, 380,000 hospitalisations and 24,000 deaths despite vaccines. We have not checked those figures against the agency’s own data.
Antivirals already exist for use after exposure; baloxavir, for example, has been approved in the US since 2020 for post-exposure prevention. A single long-acting product that protects through a season would be a different proposition, which is why several companies are working on it.
How other drug-Fc conjugates have fared
AK0406 is not the first drug-Fc approach to be tested for flu prevention. Cidara Therapeutics reported Phase 2b results in June 2025 for CD388, a conjugate of a neuraminidase inhibitor and a human Fc fragment. In more than 5,000 healthy adults aged 18 to 64, it reported protection against symptomatic, laboratory-confirmed influenza over 24 weeks of up to 76.1% against placebo at the highest dose, after a single injection.
Merck announced in November 2025 that it would acquire Cidara for about $9.2 billion, and CD388 is now in a Phase 3 trial with FDA Breakthrough Therapy designation, according to the companies.
Those are another molecule’s results and say nothing about AK0406. They show only that the concept has produced a signal in a large trial, and that the field is competitive.
What the AK0406 FDA Phase 2 trial news does not tell us
- Whether AK0406 prevents influenza in people: no efficacy data exist.
- Whether it is safe: no Phase 1 results have been released.
- How long protection might last, or how often it would be given.
- When the trial will start or how many people it will enrol.
Our assessment of the AK0406 FDA Phase 2 trial
In our assessment, the AK0406 FDA Phase 2 trial is a credible next step for an early-stage candidate, and parallel development in the United States and China shows the company intends to move quickly. But the news has been framed in some places as timely ahead of the Northern Hemisphere flu season, and the announcement gives no start date. A study run during an influenza season cannot be assumed to begin this winter.
Until Phase 1 data and the Phase 2 protocol are public, the claims about AK0406 rest on the company’s description. For another recent regulatory step in drug development, see our report on InnoCare’s China IND approval for an IBD antibody, or Fast Track status for opamtistomig, and browse our pharmaceutical coverage.
What to watch next after the AK0406 FDA Phase 2 trial clearance
- Publication of Phase 1 safety and pharmacokinetic data.
- Registration of the Phase 2 trial, with size, dose and endpoints.
- The start date and first participant dosed.
- Progress of rival long-acting influenza prevention candidates.
Frequently asked questions
What is the AK0406 FDA Phase 2 trial?
A planned multicentre, randomised, double-blind, placebo-controlled US study of AK0406 for influenza prevention in adults, cleared by the FDA on 13 October 2026.
What is AK0406?
An experimental long-acting antiviral drug-Fc conjugate from ArkBio, designed to prevent influenza A and B.
Is AK0406 approved to prevent flu?
No. It has not been approved anywhere for this use.
Does FDA clearance for the AK0406 FDA Phase 2 trial mean it works?
No. It allows the trial to proceed and says nothing about effectiveness.
When will the AK0406 FDA Phase 2 trial start?
The company has not given a start date.
How we reported this: we relied on ArkBio’s 13 October 2026 and August 2026 announcements, public regulatory information and published releases from other companies for context. We did not see the trial protocol or any Phase 1 data. Last updated: 13 October 2026. This article is news reporting and not medical advice.
